HR-9251-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Kelly Morrison (D-MN)
What it does
This bill would create a new federal grant program under the Public Health Service Act allowing the Secretary of Health and Human Services to award grants to school districts and other eligible entities for opioid overdose reversal drugs and devices (such as naloxone) in public and private K-12 schools. To receive funding, eligible entities would need to certify that each covered school has a trained staff member on-site during all operating hours, maintains an accessible supply of overdose reversal medication, and that the state attorney general has confirmed adequate civil liability protections exist for school personnel who administer the medication. The bill also expands an existing grant program to cover administration — not just prescribing — of overdose reversal drugs.
Who benefits
Students at K-12 schools who experience or witness an opioid overdose on school grounds. School nurses, health center staff, and designated school personnel who would receive training and legal liability protection. School administrators who would have a clearer framework for emergency response. Parents and families of students at risk. Communities in regions with high opioid overdose rates, including rural areas disproportionately affected by the opioid crisis. Naloxone manufacturers and distributors who would see increased institutional demand. State attorneys general offices that would gain a defined role in certifying liability protections.
Who is hurt
Taxpayers who fund the grant program. Schools or districts that do not qualify or choose not to apply may face reputational or competitive pressure relative to those that do. Private schools that lack administrative capacity to meet certification requirements may be effectively excluded. States without existing Good Samaritan or civil liability protection laws may face pressure to enact them or risk their schools being ineligible. School personnel in non-participating schools who lack access to training or supplies.
Supporters argue
Supporters argue that opioid overdoses are now the leading cause of accidental death in the United States, and that fentanyl contamination of other substances means students may unknowingly encounter opioids. They contend that naloxone is safe, non-addictive, and has no effect if administered to someone who has not taken opioids, making it a low-risk, high-reward emergency intervention. They point to existing federal programs that already fund naloxone in community settings and argue that extending this framework to schools — where trained adults are already present — is a logical and cost-effective expansion.
Opponents argue
Opponents argue that placing overdose reversal medication in elementary and secondary schools normalizes drug use among minors and may undermine prevention messaging by implying that opioid exposure is an expected school event. They contend that the bill creates unfunded administrative burdens for smaller or under-resourced schools that must meet certification requirements, coordinate with state attorneys general, and maintain trained staff at all times — potentially diverting resources from core educational functions. They also argue that the grant program adds a new federal role in local school health policy without clear evidence that school-based naloxone access materially reduces overdose mortality compared to community-based alternatives.
Constitutional context
Congress would exercise its Taxing and Spending Clause authority (Art. I, §8, cl. 1) to fund this grant program. Under NFIB v. Sebelius (2012), spending conditions are permissible so long as they do not cross into unconstitutional coercion — here, participation is voluntary and the conditions (certification, training, liability review) are modest and directly related to the program's purpose, making a coercion challenge unlikely.
Checks and balances
The executive branch (HHS Secretary) gains discretionary authority to award grants and set application requirements; Congress retains oversight through appropriations and the existing authorization structure of the Public Health Service Act.
Historical precedent
The Asthmatic Schoolchildren's Treatment and Health Management Act of 2004 established a similar federal grant model requiring schools to stock epinephrine auto-injectors and train personnel, with state liability certification as a condition of funding.